Trogenix
Last verified 2026-05-07. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $102.6Mattributed |
|---|---|
| Latest round | series-a, $86.4M, 2025-10-01attributed |
| Founded | 2023 |
| Headquarters | Edinburgh, United Kingdom |
| Industry | bio |
| Stage | series-a |
| Website | trogenix.com |
Trogenix is a biotech company developing precision cancer gene therapies using its Odysseus platform and Synthetic Super-Enhancers that target cancer-specific transcription factors. It serves patients with aggressive solid tumors such as brain cancer. Its differentiator is combining cell killing, immune activation, and protection in one therapy.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2025-10-01 | series-a | $86.4M | undisclosed |
Detected tech stack
Nginx, WordPress 7.0, Yoast SEO 27.6, Google Analytics, Google Tag Manager, Slider Revolution, jQuery Migrate 3.4.1, imagesLoaded 4.1.4, parallax.js, PHP, DoubleClick Floodlight, MySQL
Provenance
| Fact | Status | Basis |
|---|---|---|
| Series A, $86.4M | attributed | eu-startups named as publisher. No document URL on file. |
| Total raised $102.6M | attributed | eu-startups named as publisher. No document URL on file. |
| Company existence | self-reported | trogenix.com, read 2026-05-07 |
| Description | self-reported | trogenix.com, read 2026-05-07 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.